N-(2-cyanoethoxycarbonyloxy)succinimide | 242147-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-(2-cyanoethoxycarbonyloxy)succinimide
• 英文别名: (2-cyanoethyl)-N-succinimidylcarbonate；N-(2-Cyanoethoxycarbonyl)oxy succinimide；2-cyanoethyl (2,5-dioxopyrrolidin-1-yl) carbonate
• CAS: 242147-76-8
• 化学式: C₈H₈N₂O₅
• 分子量: 212.162
• InChiKey: WQWFWAMCLWRHNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  96.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-甲基-2-疏基硫酸脲 、 N-(2-cyanoethoxycarbonyloxy)succinimide 在 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以95%的产率得到[[[(2-cyanoethoxy)carbonyl]amino](methylthio)methylene]carbamic acid 2-cyanoethyl ester
  参考文献：
  名称：

  SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI

  摘要：

  本发明涉及一种新型递送系统，用于将治疗剂递送到活细胞中，更具体地说，涉及设计用于靶向和/或穿透细胞或其他感兴趣目标的新型化学基团，进一步能够将治疗剂结合到这些细胞中以进行递送，并涉及含有相同化学基团的递送系统。

  公开号：

  US20160039850A1
• 作为产物：
  描述：

  N,N'-二琥珀酰亚胺基碳酸酯 、 3-羟基丙腈 在 吡啶 作用下， 以 乙腈 为溶剂， 反应 7.0h， 以84%的产率得到N-(2-cyanoethoxycarbonyloxy)succinimide
  参考文献：
  名称：

  4′-Guanidinium-modified siRNA: a molecular tool to control RNAi activity through RISC priming and selective antisense strand loading

  摘要：

  我们提出了对4′-guanidino修饰siRNA的合成、生化、生物物理和计算评估。

  DOI：

  10.1039/c9cc04141a

文献信息

• CG base pair recognition within DNA triple helices by modified N-methylpyrrolo-dC nucleosides
  作者：Simon R. Gerrard、Mastoura M. Edrees、Imenne Bouamaied、Keith R. Fox、Tom Brown

  DOI：10.1039/c0ob00119h

  日期：——

  3-Aminophenyl-modified analogues of the bicyclic nucleoside N-methyl-3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one were synthesised and incorporated directly into triplex-forming oligonucleotides in order to utilise their extended hydrogen bonding motif for recognition of the CG base pair. All analogues demonstrated strong binding affinity and very good selectivity for CG from pH 6.2 to 7.0; a marked improvement on previous modifications.

  合成了双环核苷 N-甲基-3H-吡咯并[2,3-d]嘧啶-2(7H)-酮的 3-氨基苯基修饰类似物，并将其直接加入三聚体形成的寡核苷酸中，以利用其扩展的氢键结构识别 CG 碱基对。在 pH 值为 6.2 到 7.0 的范围内，所有类似物都表现出很强的结合亲和力和对 CG 的很好的选择性；与以前的修饰相比有了明显的改进。
• ARTIFICIAL NUCLEIC ACID, PRODUCTION METHOD THEREFOR, AND USE THEREOF
  申请人：SYSMEX CORPORATION

  公开号：US20220089634A1

  公开（公告）日：2022-03-24

  Disclosed is a compound represented by formula (1) or a salt thereof: (wherein: “Base” represents an aromatic heterocyclic group which may have a substituent or an aromatic hydrocarbon ring group which may have a substituent; A 1 represents a linear alkylene group; A 2 represents a single bond or an alkylene group; X represents an alkylene group, —O— or —S(═O) k —; R 1 and R 2 are the same as or different from each other and independently represent a hydrogen atom, etc.; and R 3 represents an amino group which may have a substituent).

  公开了一种由式（1）表示的化合物或其盐：（其中：“基”表示可能具有取代基的芳香杂环基团或可能具有取代基的芳香烃环基团；A1表示线性烷基链；A2表示单键或烷基链；X表示烷基链，-O-或-S（=O）k-；R1和R2相同或不同，独立地表示氢原子等；而R3表示可能具有取代基的氨基基团）。
• Nuclease resistant chimeric oligonucleotides
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US20030158403A1

  公开（公告）日：2003-08-21

  The present invention relates to novel nuclease-resistant oligomeric compounds and to novel methods for increasing the nuclease resistance of oligomeric compounds. In preferred embodiments of the invention, the oligomeric compounds comprise at least one modified nucleoside containing a modified sugar moiety at either the 3′ or 5′ terminus of the oligomeric compound, and further comprise at least one internucleoside linking group that is other than phosphodiester. Other preferred embodiments of the invention include methods of enhancing the nuclease resistance of oligomeric compounds comprising incorporating at least one modified nucleoside containing a modified sugar moiety at either the 3′ or 5′ terminus of an oligomeric compound.

  本发明涉及新型核酸酶抗性寡聚合物化合物以及增加寡聚合物化合物核酸酶抗性的新方法。在本发明的优选实施例中，寡聚合物化合物包括至少一个含有修饰糖基团的修饰核苷酸，该修饰核苷酸位于寡聚合物化合物的3'端或5'端，而且还包括至少一个不是磷酸二酯的核苷酸之间连接的核苷酸连接基团。本发明的其他优选实施例包括增强寡聚合物化合物核酸酶抗性的方法，其中包括将至少一个含有修饰糖基团的修饰核苷酸合并到寡聚合物化合物的3'端或5'端。
• Nucleosidic and non-nucleosidic folate conjugates
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US20020049163A1

  公开（公告）日：2002-04-25

  Oligonucleotide-folate conjugates are described wherein folates are conjugated to one or more sites on an oligonucleotide including the 2′-, 3′-, 5′-, nucleobase and internucleotide linkage sites. The folate can be attached via the &agr;- or &ggr;-carboxylate, optionally through a linking group. Methods for the regiospecific synthesis of the conjugates are diclosed. Also disclosed are nucleosidic and non-nucleosidic linkers conjugated to folic acid and related folates.

  描述了寡核苷酸-叶酸共轭物，其中叶酸与寡核苷酸的2'-、3'-、5'-、核碱基和核苷酸间连接位点之一或多个位点结合。叶酸可以通过α-或γ-羧酸酯连接，可选地通过连接基团连接。公开了合成共轭物的区域特异性方法。还公开了与叶酸及相关叶酸共轭的核苷酸和非核苷酸连接剂。
• System for delivering therapeutic agents into living cells and cells nuclei
  申请人：Segev David

  公开号：US20060160763A1

  公开（公告）日：2006-07-20

  A novel class of oligomeric compounds designed for forming conjugates with biologically active substances and delivering these substances to a desired bodily target are disclosed. Novel conjugates of these oligomeric compounds and biologically active moieties, pharmaceutical compositions containing such conjugates, and uses thereof as delivery systems for delivering the biologically active substances to a desired target are further disclosed. Processes of preparing the conjugates and the oligomeric compounds and novel intermediates designed for and used in these processes are also disclosed.

  本发明披露了一种新型寡聚化合物，旨在与生物活性物质形成共轭物，并将这些物质传递到所需的身体靶点。本发明还披露了这些寡聚化合物和生物活性基团的新型共轭物，包含这种共轭物的药物组合物以及将其用作传递生物活性物质到所需靶点的传递系统的用途。本发明还披露了制备共轭物和寡聚化合物的过程以及设计和用于这些过程的新型中间体。